908 Devices Sells Bioprocessing PAT Portfolio to Repligen
Deal News | Mar 04, 2025 | Paul Hastings
908 Devices Inc., a Boston-based innovator in chemical analysis devices, has sold its desktop bioprocessing process analytical technology (PAT) portfolio to Repligen Corporation, a leader in the life sciences and bioprocessing technology. This transaction was advised by Paul Hastings LLP, showcasing its prominence in Boston’s life sciences and technology market. Ian Engstrand, along with a sizeable team from Paul Hastings, guided the transaction. Paul Hastings is renowned for its expertise across 17 core practice areas, serving top investment banks, asset managers, and corporations worldwide.
Sectors
- Life Sciences
- Chemical Analysis
- Legal Services
Geography
- United States – Both 908 Devices and Paul Hastings are based in the United States, with a strong emphasis on the Boston market.
Industry
- Life Sciences – The transaction involves the sale of bioprocessing technology and devices, which are critical components in the life sciences industry.
- Chemical Analysis – 908 Devices specializes in chemical analysis devices, a part of the broader chemical industry.
- Legal Services – Paul Hastings is providing advisory services, representing the legal sector’s involvement in the transaction.
Financials
- – The article does not disclose the financial details of the transaction.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| 908 Devices Inc. | Target Company | Company | A Boston-based company specializing in handheld and desktop devices for chemical analysis. |
| Repligen Corporation | Bidding Company | Company | A life sciences company focused on bioprocessing technology leadership. |
| Paul Hastings LLP | Legal Advisor | Company | A premier law firm advising 908 Devices in the transaction. |